Sensibilidad de microorganismos gramnegativos de infecciones intraabdominales y evolución de los aislados con β-lactamasas de espectro extendido en el estudio smart en españa (2002-2010);Antimicrobial susceptibility of gram-negative organisms from intra abdominal infections and evolution of isolates with extended spectrum β-lactamases in the smart study in spain (2002-2010)

Revista Espanola de Quimioterapia

Volumn 24, Issue 4, 2011, Pages 223-232

  Cantón, Rafael ^a,b   Loza, Elena ^a   Aznar, Javier ^c   Calvo, Jorge ^d   Cercenado, Emilia ^e   Cisterna, Ramón ^f   Romo, Fernando González ^g   Hontangas, José Luis López ^h   Calvo, Carmen Rubio ⁱ   Barrenechea, Ana Isabel Suárez ^j   Tubau, Fe ^k   Weber, Irene ^l   Yuste, Patricia ^m   Cavanillas, Rafael ^m  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m Medical affairs Merck sharp and Dohme ltd   (Spain)

more..

Author keywords

Carbapenems; Extended spectrum lactamases; Intraabdominal infections; Surveillance study

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; BETA LACTAMASE;

ABDOMINAL INFECTION; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; CITROBACTER FREUNDII; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MORGANELLA MORGANII; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; TREATMENT RESPONSE; ABDOMEN; AGE; AGED; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; ENVIRONMENTAL MONITORING; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; KLEBSIELLA INFECTION; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; SPAIN;

ABDOMEN; ADULT; AGE FACTORS; AGED; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; ENVIRONMENTAL MONITORING; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE AEROBIC BACTERIA; GRAM-NEGATIVE ANAEROBIC BACTERIA; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SPAIN;

EID: 84856043210     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bush K. Alarming ß-lactamase-mediated resistance in multidrug- resistant Enterobacteriaceae. Curr Opin Microbiol 2010; 13: 558-64.
2. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 (Suppl S1): 1-7.
3. Cantón R. Role of the microbiology laboratory in infectious disease surveillance, alert and response. Clin Microbiol Infect 2005; 11 (Suppl 1): 3-8.
4. Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum ß-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clinical Microbiol Infect 2011 Apr 25. doi: 10.1111/j.1469-0691.2011.03550.x.
5. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009; 8: 421-37.
6. Nicoletti G, Nicolosi D, Rossolini GM, Stefani S. Intra-abdominal infections: etiology, epidemiology, microbiological diagnosis and antibiotic resistance. J Chemother 2009; 21 (Suppl 1): 5-11.
7. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra- abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-21.
8. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 133-64.
9. Guirao X, Arias J, Badía JM, García-Rodríguez JA, Mensa J, Alvarez- Lerma F, et al. Recommendations in the empiric anti-infective agents of intra-abdominal infection. Rev Esp Quimioter 2009; 22: 151-72.
10. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN, ed.: APIC Infection Control and Applied Epidemiology: Principles and Practice. St. Louis: Mosby; 1996: pp. A1-A20.
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - 8th Edition. Document, M07-A8. Wayne, PA: CLSI, 2009.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Document M100-S21. Wayne, PA: CLSI, 2011.
13. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 1.3, January 2011.
14. Baquero F, Hsueh PR, Paterson DL, Rossi F, Bochicchio GV, Gallagher G, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 Results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2009; 10: 99-104.
15. Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, et al. 2008 Asia-Pacific SMART Group. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36: 408-14.
16. Hawser S, Hoban D, Bouchillon S, Badal R, Carmeli Y, Hawkey P. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis 2011; 30: 173-9.
17. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F. Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum ß-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54: 3043-6.
18. Brook I. Microbiology and management of abdominal infections. Dig Dis Sci 2008; 53: 2585-91.
19. Lumb J. Carbapenems in the treatment of intra-abdominal infection. Report from the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 10-13 April 2010. Future Microbiol 2010; 5: 1165-6.
20. Coque TM, Baquero F, Cantón R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13(47): 19044.
21. Guembe M, Cercenado E, Alcalá L, Marín M, Insa R, Bouza E. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007. Rev Esp Quimioter.2008; 21: 166-73.
22. Ofner-Agostini M, Simor A, Mulvey M, McGeer A, Hirji Z, Mc- Cracken M et al. Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals. Can J Infect Dis Med Microbiol 2009; 20: e43-8.
23. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum ß-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
24. Cantón R, Ruiz-Garbajosa P. Co-resistance: an opportunity for the bacteria and resistance genes. Curr Opin Pharmacol 2011; 11:477-85.
25. Endimiani A, Paterson DL. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum ß-lactamases. Semin Respir Crit Care Med 2007; 28: 646-55.
26. Pitout JD. Infections with extended-spectrum ß-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
27. Tato M, Coque TM, Ruíz-Garbajosa P, Pintado V, Cobo J, Sader HS et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo- ß-lactamase in Spain: toward endemicity? Clin Infect Dis 2007; 45: 1171-8